Herpes Vaccine Research Blog

Halford Formal Photo

WHO AM I?

My name is Bill Halford and I am an Associate Professor of Microbiology and Immunology at Southern Illinois University School of Medicine in Springfield, Illinois.  I have studied herpes simplex virus (HSV) biology since 1991, and I became interested in trying to develop a safe and effective HSV-2 vaccine in 2006.  There are at least 100 individuals in the world who are actively pursuing a HSV-2 vaccine, and I am one of these many researchers.  In this blog, I will try to cut through the nomenclature and statistics and explain in relatively straightforward terms what we know about HSV-2 vaccines and what we need to do next to advance a safe and effective HSV-2 vaccine to human clinical trials.

 

DISCLAIMER

The author of this website, Bill Halford, is an employee of the Southern Illinois University School of Medicine in Springfield, Illinois.  The viewpoints expressed on this website are solely that of the author, and should not be construed as an official statement of the policies, procedures, or opinions of Southern Illinois University, the School of Medicine, or any of the academic departments contained therein.

 

BACKGROUND ON HSV-2 INFECTIONS AND GENITAL HERPES

Genital herpes caused by herpes simplex virus type 2 (HSV-2) remains a huge medical and public health problem.  About 540 million people between the ages of 14 and 49 are life-long carriers of the HSV-2 virus.  About 5% of HSV-2 carriers live with genital herpes outbreaks that recur once every 2 to 12 months over the duration of their lives.  Each outbreak can last from 2 to 20 days in duration, and is physically uncomfortable and emotionally distressing.  Antiviral drugs such as acyclovir or valacyclovir (valtrex) reduce, but do not prevent the symptoms of recurrent genital herpes.  Likewise, antiviral drugs have not slowed the spread of HSV-2 infection at all; 10 to 20 million per year continue to acquire new HSV-2 infections from the hundreds of millions of people who already carry HSV-2.

HSV-2 genital herpes has been described as a silent epidemic.  This term is apt, as HSV-2 exists all around us and is carried by friends and family members, but people are reluctant to disclose that they are infected with HSV-2 as there remains a historical stigma associated with this infection.  Many people who have HSV-2 have had one or just a few sexual partners, and many teenagers who acquire HSV-2 have the misfortune of acquiring HSV-2 with their first sexual partner.  Nonetheless, the HSV-2 infection bears a social stigma, and people do not openly discuss their infection status.  Thus, most non-HSV-2 carriers assume that HSV-2 genital herpes is a relatively uncommon condition.  This is dead wrong.  One number helps put the problem into perspective; each of our children has a 1-in-10 chance of contracting a HSV-2 infection before they are married.

Aside from the individual suffering caused by recurrent genital herpes, HSV-2 infections can cause more severe complications such as HSV-2 infections of newborns as they pass through the vagina / birth canal.  The immune system of neonates is not yet developed, and thus HSV-2 infections in newborn babies can be devastating often resulting in death or severe mental / cognitive impairment, as HSV-2 infection can spread to the central nervous system of newborns.

 

THE POTENTIAL UTILITY OF A HSV-2 VACCINE

Effective vaccines have been responsible for the eradication and/or control of many viral diseases such as smallpox, yellow fever, red measles, mumps, German Measles, hepatitis B, chickenpox, and poliomyelitis.  In principle, there is no reason that a safe and effective HSV-2 vaccine could not be deployed in the human population to prevent HSV-2 genital herpes.

The applications of a safe and effective genital herpes vaccine would be two-fold.

First, an effective HSV-2 vaccine could be given to adolescents or prospective sexual partners of those who already carry the HSV-2 virus.  Exposure to an effective HSV-2 vaccine would bolster the immune system of such individuals such that their bodies were at least 100 times better prepared to repel the real (wild-type) HSV-2 pathogen if they were exposed later in life.  Such a “preventative HSV-2 vaccine” could be used to prevent ~20 million per year from newly acquiring the HSV-2 virus.

Second, an effective HSV-2 vaccine could be given to those who suffer from frequent outbreaks of recurrent genital herpes.  Such a “therapeutic HSV-2 vaccine” could be used to reduce the frequency and duration of genital herpes outbreaks in those ~40 million people worldwide who suffer from this chronic viral disease.  This latter application of a HSV-2 vaccine (i.e., to reduce symptoms in those who already carry the HSV-2 virus) would be more experimental, and less of a sure thing than a preventative HSV-2 vaccine.  Nonetheless, there are several publications dating back to the 1950s that claim such an effect has been obtained by treatment with a variety of vaccine formulations including inactivated-preparations of HSV virion particles.  Therefore, once a safe and effective HSV-2 preventative vaccine is identified, it will be relevant to determine if it has potential  to also serve as a therapeutic HSV-2 vaccine.

 

WHY DO WE STILL LACK AN EFFECTIVE HSV-2 VACCINE?

This is the million-dollar question and the focus of the Herpes Vaccine Research Blog.

I envision posts on this blog serving one of three general purposes, and these will be discussions of:

1.  The science of HSV-2 vaccines

2.  Moving a safe and effective live-attenuated HSV-2 vaccine into human trials

What I hope to make clear through the development of this blog is that a safe and effective HSV-2 vaccine lies within our grasp, but what we lack is a critical mass of support to advance such a HSV-2 vaccine to human clinical trials.  The primary barriers to the advancement of an effective HSV-2 vaccine are (1) misinformation and (2) a pre-conceived notion that live-attenuated HSV-2 vaccines should not be investigated or considered for use as a human vaccine.

One of the central purposes of this blog will be to (try to) simply explain why past HSV-2 vaccines have not worked, and define what we need to do differently in the future if we intend to end the needless suffering caused by genital herpes.  Make no mistake…..HSV-2 genital herpes is a vaccine-preventable disease.  However, the field of HSV-2 vaccine research is long overdue for a “course correction.”  I hope that this blog serves as a vehicle to increase the public’s understanding of what we need to do differently in the future if we hope to make HSV-2 genital herpes a disease of the past.

– Bill Halford

551 thoughts on “Herpes Vaccine Research Blog

  1. Rylee says:

    When will the theravax be available to the general public, meaning not clinical trials- but anyone that can travel to receive it? When is the last clinical trial set to run and where will the vaccine be available? People are suffering.

    Like

  2. Mark says:

    This whole situation with Dr. Veloz and Minerva Labs seems confusing and suspicious. I would think that Rational Vaccines, in their interest of its emerging reputation as a legitimate pharmaceutical start-up, would want to issue some type of official statement or clarification on this issue.

    Like

    • Vitamin C says:

      Hi Mark, I don’t see any reason for suspicion. There have been press releases issued. Dr. Halford had been cited in numerous peer reviewed journals and he was a well published scientist who was a well documented professor at Southern Illinois University. Dr. Halford just passed away a couple of months ago from a long battle with cancer therefore Rationale Vaccines (company releasing Theravax) are likely in the process of reorganizing and GRIEVING due to the loss of the key research (and friend). As a daily blog follower for 3 years, it is my understanding that Rationale Vaccines it tasked with getting this vaccine to market without a major funder. My understanding from press releases, that they are courting some interested parties. I am hypothesizing, that because no big funder has signed on the dotted line yet, that Rational Vaccines needs to insure they remain financially viable.

      Like

    • Vitamin C says:

      It’s a miracle that Rationale Vaccines has had their first human trial. The company has had a major blow…Dr. Halford,the lead researcher sadly passed away from cancer just recently. I no longer worry about HSV because I know, and feel secure with the knowledge that the first ever human trial was a success. Also, Rationale Vaccines has taken the bold and innovate step to skip FDA approval and seek safe harbour in countries where vaccine approval is much more practical!!! So, based ony understanding of info provided by Dr. Hey, Agustin and Rationale Vaccines, the vaccine will be available sooner rather than later!!!

      Like

  3. Dr feroz ahmadi says:

    how can foreign patients get the shots at dominican republic ? Dr Veloz is doing consultation in USA so how do foreign people avail the vaccine ???

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s